Nintedanib (OFEV) seems to inhibit the activation of fibroblasts and to exert an anti-fibrotic effect in mouse models of systemic…
Articles by Patrícia Silva, PhD
Inventiva, a drug discovery company focused on treatments for fibrosis, oncology, and rare diseases, discussed one of its most advanced clinical products, IVA337,…
At last week’s 4th Systemic Sclerosis World Congress in Lisbon, Portugal, a team of researchers presented data about the role of…
Scleroderma News correspondent Dr. Ana de Barros conducted an exclusive interview with Dr. Colin Meyer, chief medical officer and vice president…
New data was recently presented regarding Actelion Pharmaceuticals’ therapies and strategies to improve clinical outcomes in patients with pulmonary arterial…
At the 4th Systemic Sclerosis World Congress, recently held in Lisbon, Portugal, an international team of researchers led by…
Digital ulcers have a significant clinical burden in patients with systemic sclerosis. In a study presented today, Feb. 19, at the…
A EUSTAR study on organ manifestations in the early course of systemic sclerosis (SSc) was presented today, Feb. 19, by…
https://sclerodermanews.com/wp-content/uploads/videos/Sequence%2001_1.mp4 Scleroderma News Today’s exclusive interview with Professor Christopher Denton, lead…
Fibrocell Science, Inc., recently highlighted the latest advancements in its pipeline of products focused on autologous cell and gene therapy treatments for…